Has the Enemy "MET" Its Match? Subgroup Analysis Results from VISION Study.
Where this comes from
- Record sourced from PubMed, PMID 34983790.
- Also identified by DOI 10.1158/1078-0432.CCR-21-4109.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Emerging therapies have recently received approval for the treatment of MET exon 14 skipping non-small cell lung cancer (NSCLC). Further characterization of these therapies, such as tepotinib, is needed to identify patient subgroups most likely to derive benefit from these novel agents. See related article by Le et al., p. 1117.
Medical subject headings
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms